In particular, counteracting the cellular stress, targeting the S1 protein or using the anti-NKG2A monoclonal antibody monalizumab, currently in use for management of rheumatoid arthritis and several neoplastic disorders [43], might represent new anti-SARS-CoV-2 strategies to enhance the innate immune response at the early stage of the disease, inducing mucosal immunity that might lead to a long-term protection against SARS-CoV-2 infection [44]. Here, PSMD1 is linked to neoplastic disease or syndrome.